BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 38570761)

  • 1. Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment.
    Jensen RH
    Dan Med J; 2016 Oct; 63(10):. PubMed ID: 27697142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Causative Agents of Aspergillosis Including Cryptic Aspergillus Species and A. fumigatus].
    Toyotome T
    Med Mycol J; 2016; 57(4):J149-J154. PubMed ID: 27904060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hospital distribution, seasonality, time trends and antifungal susceptibility profiles of all Aspergillus species isolated from clinical samples from 2015 to 2022 in a tertiary care hospital.
    Franconi I; Rizzato C; Ghelardi E; Lupetti A
    BMC Microbiol; 2024 Apr; 24(1):111. PubMed ID: 38570761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distribution of Aspergillus species and prevalence of azole resistance in clinical and environmental samples from a Spanish hospital during a three-year study period.
    Lucio J; Alcazar-Fuoli L; Gil H; Cano-Pascual S; Hernandez-Egido S; Cuetara MS; Mellado E
    Mycoses; 2024 Apr; 67(4):e13719. PubMed ID: 38551063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Species distribution and antifungal susceptibility of clinical Aspergillus isolates: A multicentre study in Taiwan, 2016-2020.
    Wang HC; Hsieh MI; Choi PC; Wu WL; Wu CJ;
    Mycoses; 2023 Aug; 66(8):711-722. PubMed ID: 37186489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Azole resistance in Aspergillus species in Southern Taiwan: An epidemiological surveillance study.
    Chen YC; Kuo SF; Wang HC; Wu CJ; Lin YS; Li WS; Lee CH
    Mycoses; 2019 Dec; 62(12):1174-1181. PubMed ID: 31549427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiology, Drug Susceptibility, and Clinical Risk Factors in Patients With Invasive Aspergillosis.
    Wang Y; Zhang L; Zhou L; Zhang M; Xu Y
    Front Public Health; 2022; 10():835092. PubMed ID: 35493371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective survey of Aspergillus species isolated from clinical specimens and their antifungal susceptibility: A five-year single-center study in Japan.
    Toyotome T; Saito S; Koshizaki Y; Komatsu R; Matsuzawa T; Yaguchi T
    J Infect Chemother; 2020 Feb; 26(2):321-323. PubMed ID: 31564504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paradigm Shift:
    Franconi I; Rizzato C; Tavanti A; Falcone M; Lupetti A
    J Fungi (Basel); 2023 Oct; 9(10):. PubMed ID: 37888268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The WHO fungal priority pathogens list as a game-changer.
    Fisher MC; Denning DW
    Nat Rev Microbiol; 2023 Apr; 21(4):211-212. PubMed ID: 36747091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seasonal variation of airborne fungal diversity and community structure in urban outdoor environments in Tianjin, China.
    Nageen Y; Wang X; Pecoraro L
    Front Microbiol; 2022; 13():1043224. PubMed ID: 36699604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and Microbiological Characteristics of Aspergillosis at a Chinese Tertiary Teaching Hospital.
    Xiao C; Qiao D; Xiong L; Tian W; Wang D; Deng S; Guo J
    Infect Drug Resist; 2022; 15():7249-7257. PubMed ID: 36533254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19-associated pulmonary aspergillosis: an underdiagnosed or overtreated infection?
    Rouzé A; Martin-Loeches I; Nseir S
    Curr Opin Crit Care; 2022 Oct; 28(5):470-479. PubMed ID: 35950729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in the Prevalence of Amphotericin B-Resistance (AmBR) among Clinical Isolates of Aspergillus Species.
    Fakhim H; Badali H; Dannaoui E; Nasirian M; Jahangiri F; Raei M; Vaseghi N; Ahmadikia K; Vaezi A
    J Mycol Med; 2022 Nov; 32(4):101310. PubMed ID: 35907396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cryptic aspergillosis: a rare entity and a diagnostic challenge.
    R L; Ninan MM; Kurien R; N A F; Sahni RD; Michael JS
    Access Microbiol; 2022; 4(4):000344. PubMed ID: 35812705
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.